Optibrium Introduces StarDrop 6.5

- *Novel features include modelling for drug metabolism prediction and virtual library enumeration*
- *Enhanced data visualisation environment for more efficient data analysis and project management*

CAMBRIDGE, UK, 19 June, 2018 – Optibrium™, a developer of software for drug discovery, today announced the launch of version 6.5 of StarDrop™ that provides a complete platform for small molecule design, optimisation and data analysis. The latest release introduces **WhichP450**, a new feature in StarDrop's P450 metabolism module that predicts which human Cytochrome P450 enzymes are the major metabolising isoforms for a novel compound. Understanding how a compound is metabolised enables identification and analysis of its potential metabolites, and guides the design of molecules with a reduced risk of drug-drug interactions or variations in exposure across the patient population.

Also included in the latest version of StarDrop is novel **R-group clipping** functionality that quickly transforms chemical building blocks into their corresponding substituents for enumeration of virtual libraries and the exploration of new compound ideas. Associated data, such as inventory and cost for each building block, are linked with the enumerated compounds to facilitate ordering for synthesis of the best compounds.

The new features are introduced in parallel with an **enhanced data visualisation environment** offering more chart types, additional formatting options and a streamlined user interface, enabling publication-quality graphics to be created in just a few clicks. This is teamed with a new 'dashboard' capability, combining multiple interactive plots in a configurable project view, enabling scientists, team leaders and managers to track the progress of a project at a glance.

Dr Matthew Segall, Optibrium's CEO, commented: "We continue to invest in leading-edge research to bring the latest modelling approaches to our users in an intuitive interface. StarDrop's enhanced capabilities ensure that scientists can quickly understand structure-activity relationships, identify potential liabilities and design new compounds with the highest chance of success. This leads to better decisions and shorter project timelines."

For further information on Optibrium or StarDrop, please visit www.optibrium.com, contact info@optibrium.com or call +44 1223 815900.

ENDS

F5-6 Blenheim House, Cambridge Innovation Park
Denny End Road, Cambridge
CB25 9PB, UK

Tel: +44 1223 815900
Fax: +44 1223 815907

Email: info@optibrium.com
Website: www.optibrium.com

Notes to Editors:

For high resolution image please email sarah.jeffery@zymecommunications.com

Media contact

Sarah Jeffery
Zyme Communications
E-mail: sarah.jeffery@zymecommunications.com
Phone: +44 (0) 7771 730919

Optibrium

Nick Foster
Head of Commercial Operations
E-mail: nick.foster@optibrium.com
Phone: +44 (0) 1223 815900

About Optibrium Ltd.

Optibrium provides elegant software solutions for small molecule design, optimisation and data analysis. The company's lead product, StarDrop, is a comprehensive suite of integrated software with a highly visual and user-friendly interface. StarDrop enables a seamless flow from the latest data through to predictive modelling and decision-making regarding the next round of synthesis and research, improving the speed, efficiency, and productivity of the discovery process.

Founded in 2009, Optibrium is headquartered in Cambridge, UK with offices in Boston and San Francisco, USA. Optibrium continues to develop new products and research novel technologies to improve the efficiency and productivity of the drug discovery process. Optibrium works closely with its broad range of customers and collaborators that include leading global pharma, agrochemical and flavouring companies, biotech and academic groups.

For further information visit www.optibrium.com or join in discussions on improving the productivity of drug discovery at www.optibrium.com/community.